SCHEMBL7385448

SCHEMBL7385448

C(#CC1CC1)c1nccs1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.47
CYP1A2 P05177 1/20 0.36
PTPN11 Q06124 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TSHR P16473 2/20 0.33
HTT P42858 1/20 0.33
ALDH1A1 P00352 1/20 0.33
NOS1 P29475 1/20 0.33
HSD17B10 Q99714 1/20 0.33
IKBKB O14920 1/20 0.33
ACACB O00763 1/20 0.32
PGK1 P00558 1/20 0.32
EPHX2 P34913 1/20 0.32
KDM4E B2RXH2 1/20 0.32
FBP1 P09467 1/20 0.31
PDK1 Q15118 1/20 0.31
IDO1 P14902 2/20 0.31
PDE10A Q9Y233 1/20 0.31
NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7419628 0.91 GRM5 (0.41) GRM5CYP1A2PTPN11MEN1KMT2A
SCHEMBL4861899 0.91 GRM5 (0.47) GRM5CYP1A2MEN1KMT2ATSHR
SCHEMBL7388499 0.85 GRM5 (0.39) GRM5MEN1KMT2ATSHRHTT
SCHEMBL7420330 0.84 GRM5 (0.42) GRM5CYP1A2MEN1KMT2ATSHR
SCHEMBL28748970 0.74
SCHEMBL19778794 0.70
SCHEMBL16116343 0.70
SCHEMBL15870897 0.67 GRM5 (0.60) GRM5TSHRALDH1A1NOS1HSD17B10
SCHEMBL7419586 0.66 GRM5 (0.41) GRM5ACACB
SCHEMBL13726266 0.65 GRM5 (0.48) GRM5TSHRALDH1A1NOS1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130053382-A1 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) PALIWAL SUNIL (US) 2013-02-28 US disclosed
EP-1214303-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF Merck & Co., Inc. (US) 2002-06-19 EP disclosed
WO-2001016121-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF MERCK & CO., INC. (US) 2001-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053382-A1 Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) PDK1, PDPK1, PDK3 GRM5 2798/4885CYP1A2 4706/4885PTPN11 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.